AML Hub Satellite Symposium highlights: How does MRD impact outcome of stem cell transplantation in AML – now and in the future?

At the 46th Annual Meeting of the European Society for Blood and Marrow...

AML Hub Satellite Symposium: Round table discussion and conclusions from the Chair

The virtual AML Hub Satellite Symposium at the 46th Annual Meeting of the European Society for Blood and Marrow...

Why should we use MRD assessment post hematopoietic stem cell transplantation?

Professor Charles Craddock, University of Birmingham, Birmingham, UK, presented the topic ‘Why should we use MRD...

Does current evidence support the use of MRD-guided treatment before transplant in patients with AML?

Professor Adriano Venditti, University of Rome Tor Vergata, Rome, IT, presented the topic ‘Does...

How does the mutation profile differ between patients with MDS–AML and de novo AML?

During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to James Yu, AdventHealth Orlando, Orlando, US....

How safe and efficacious is conditioning with radiolabeled anti-CD45 antibody 211-At-BC8-B10?

During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Brenda Sandmaier, Fred Hutchinson...

Beat AML Master trial: can we use precision medicine to treat older patients with AML?

The Beat AML Master trial is an umbrella study which contains 11 sub-studies covering the most prominent subtypes...

Gemtuzumab ozogamicin for salvage CBF-AML: A case report

During the 2nd How to Diagnose and Treat Acute Leukaemia conference organized by the European School of Haematology (ESH), there was an...

Introduction to a series of podcasts on the use of venetoclax combinations in mutation subtypes of AML

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub...

ASH 2020: Highlights for patients with TP53-mutated AML

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Uwe Platzbecker, University of Leipzig...

Why should we assess variant allelic frequency in TP53-mutated AML?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Nicholas J. Short, MD...

TP53 mutations linked to increased immune infiltration and IFN-γ signaling in patients with AML

Patients with acute myeloid leukemia (AML) are considered to be in the high cytogenetic risk category if...